Skip to main content
SpringerLink
Log in

Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65(10): 1391–418

    Article  PubMed  CAS  Google Scholar 

  2. British national formulary. Sept 2005 No. 50 [online]. Available from URL: http://www.bnf.org[Accessed 2005 Oct 12]

  3. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication no. 98-4083. Washington, DC: US Government Press, 1998 Sep

  4. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 Nov 17; 353(20): 2111–20

    Article  PubMed  CAS  Google Scholar 

  5. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1: 352–4

    Article  PubMed  CAS  Google Scholar 

  6. Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp 1972; 14: 726–38

    PubMed  CAS  Google Scholar 

  7. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537–45

    Article  PubMed  CAS  Google Scholar 

  8. US Food and Drug Administration. Dietary supplements containing ephedrine alkaloids: final rule summary [online]. Available from URL: http://www.fda.gov[Accessed 2005 Oct 12]

  9. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873–83

    Article  PubMed  CAS  Google Scholar 

  10. Aydin N, Topsever P, Kaya A, et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004; 202: 173–80

    Article  PubMed  CAS  Google Scholar 

  11. Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 6: 431–7

    Article  Google Scholar 

  12. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999; 20(2): 119–31

    Article  PubMed  CAS  Google Scholar 

  13. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094

    PubMed  Google Scholar 

  14. Hauner H, Meier M, Jockel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453–9

    Article  PubMed  CAS  Google Scholar 

  15. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116–23

    Article  PubMed  CAS  Google Scholar 

  16. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5–11

    Article  PubMed  CAS  Google Scholar 

  17. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160(14): 2185–91

    Article  PubMed  CAS  Google Scholar 

  18. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61

    Article  PubMed  CAS  Google Scholar 

  19. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049–56

    Article  PubMed  CAS  Google Scholar 

  20. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633–41

    Article  PubMed  CAS  Google Scholar 

  21. Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129–35

    PubMed  CAS  Google Scholar 

  22. Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321–5

    PubMed  CAS  Google Scholar 

  23. Griffen L, Anchors M. The “Phen-Pro” diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278–9

    Article  PubMed  CAS  Google Scholar 

  24. Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820–5

    Article  PubMed  CAS  Google Scholar 

  25. VanGaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–97

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications. Drugs Ther. Perspect 22, 7–11 (2006). https://doi.org/10.2165/00042310-200622010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622010-00003

Search

Navigation